<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896467</url>
  </required_header>
  <id_info>
    <org_study_id>COL-0701</org_study_id>
    <secondary_id>CDR0000626737</secondary_id>
    <secondary_id>COL-IPSY</secondary_id>
    <secondary_id>COL-RCB 2007-A00223-50</secondary_id>
    <secondary_id>INCA-RECF0480</secondary_id>
    <nct_id>NCT00896467</nct_id>
  </id_info>
  <brief_title>Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy</brief_title>
  <official_title>Psychological and Emotional Impacts of Participation in Randomized Clinical Studies in Medical Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information from patients who received treatment for metastatic cancer&#xD;
      while participating in a phase II or phase III randomized clinical trial and from patients&#xD;
      receiving standard treatment off-trial may help doctors learn more about the psychological&#xD;
      and emotional results of being in a clinical trial.&#xD;
&#xD;
      PURPOSE: This clinical trial is comparing the psychological and emotional impact of&#xD;
      participating in a randomized clinical trial with the impact of standard treatment in&#xD;
      patients with metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the psychological and emotional consequences in patients who underwent&#xD;
           first-line antitumor treatment (chemotherapy or targeted therapy) for metastatic disease&#xD;
           while participating in a phase II or III randomized clinical trial vs patients who&#xD;
           underwent standard first-line treatment off-trial.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To measure and compare the temporal variation of psychological and emotional&#xD;
           consequences during and after completion of or stopping of treatment.&#xD;
&#xD;
        -  To measure and compare the degree of knowledge of the implications of participating in a&#xD;
           clinical study vs the benefits of standard off-trial treatment and evaluate the impact&#xD;
           on psychological and emotional experience.&#xD;
&#xD;
        -  To evaluate the relationship between the use of adjustment strategies and emotional&#xD;
           regulation and psychological and emotional experiences in both of these situations.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients complete four questionnaires, including assessment of symptoms of anxiety and&#xD;
      depression (HADS), quality of life (QLQ-30), adjustment strategies (WCC), and regulation of&#xD;
      emotional behavior (ERQ), during their first course of treatment, after the first evaluation&#xD;
      of treatment effectiveness, and one week after completion of treatment. During their first&#xD;
      evaluation, patients also complete a questionnaire on the modalities of randomized clinical&#xD;
      trials and their impact on care (ICEC-R).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Quality of life as assessed by the QLQ-30 questionnaire</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms of anxiety and depression as assessed by the HADS questionnaire</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjustment strategies and emotional regulation as assessed by the WCC and ERQ questionnaires</measure>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anal Cancer</condition>
  <condition>Anxiety Disorder</condition>
  <condition>Breast Cancer</condition>
  <condition>Depression</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cancer&#xD;
&#xD;
               -  Metastatic disease for which the median progression-free survival is â‰¥ 4 months&#xD;
&#xD;
               -  Breast, digestive, kidney, lung&#xD;
&#xD;
          -  Receiving first-line antitumor therapy (i.e., chemotherapy or targeted therapy) as&#xD;
             part of either:&#xD;
&#xD;
               -  Phase II or III randomized clinical trial&#xD;
&#xD;
               -  Standard treatment off-trial&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status (PS) 0-3 or Karnofsky PS 50-100%&#xD;
&#xD;
          -  No psychological or physical inability to respond to a questionnaire&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No psychotropic treatment, except for antidepressants, anxiolytics, or sleeping pills&#xD;
             taken for more than 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Clisant</last_name>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire URECA</name>
      <address>
        <city>Villeneuve d'Ascq</city>
        <zip>59653</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2009</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>anxiety disorder</keyword>
  <keyword>depression</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>stage IV anal cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>small intestine cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

